News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
MindBio Therapeutics Corp. reports Phase 2A clinical trials results showing substantial and sustained reduction in depression symptoms with MB22001, a self-administered microdose of LSD -
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking depression trial using microdoses of psychedelic medicines, showing significant improvements in anxiety, stress, and depression levels -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. presents groundbreaking women's health trials for microdosing treatments, showcasing Dr. Rachael Sumner and upcoming data release on Phase 2A trial results. Chief Executive Justin Hanka discusses future growth plans
